Across clinical guidelines, there is consensus that ER, PR, and HER2 testing are central for early breast cancer (EBC) risk assessment, with IHC and confirmatory in situ hybridization (ISH) used to classify tumors as luminal, HER2-positive, or TNBC [293,294,295,296,297,298,299]. Here, ESR1 is linked to breast cancer.